Phase II Treatment of Adults With Recurrent Supratentorial Low Grade Glioma With Gliadel Wafers
OBJECTIVES:
- Determine the antitumor activity of Gliadel wafers (carmustine) in the treatment of
recurrent supratentorial low grade glioma.
- Assess the toxicity of this therapy in these patients.
OUTLINE: Patients are stratified by disease (fibrillary astrocytoma vs oligodendroglioma or
mixed glioma).
Patients receive up to 8 Gliadel wafers (containing carmustine) implanted in the resected
tumor cavity.
Patients are followed every 2 months.
PROJECTED ACCRUAL: This study will accrue a maximum of 68 patients within 18-24 months.
Interventional
Primary Purpose: Treatment
Henry S. Friedman, MD
Study Chair
Duke University
United States: Federal Government
1706
NCT00003467
January 1998
February 2004
Name | Location |
---|---|
Duke Comprehensive Cancer Center | Durham, North Carolina 27710 |